Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Genmab acquires Merus for $8B, FDA approves Alzheimer’s blood test, and Trump Administration secures drug pricing deals. Complete biotech industry analysis. 1. Genmab’s $8 Billion
The final week of September brought seismic shifts across the pharmaceutical and biotechnology sectors, with an $8 billion oncology acquisition, leadership changes at Big Pharma
The pharmaceutical industry’s marketing playbook is about to get a major rewrite. The FDA has announced an aggressive campaign against misleading drug advertisements, signaling the
Concord Biotech Plummets: Shares crashed 27% by Feb 14, capping a brutal week after a failed trial sank hopes—smallcap biotech’s reeling. Economic Times calls it
Latent Labs Unveils AI: On Feb 13, Latent Labs launched an AI platform targeting proteins and RNA for drug discovery, boasting 30% faster hit rates.
Pharma Bribery Risk Looms: Trump’s Feb 12 executive order paused enforcement of the Foreign Corrupt Practices Act, stirring fears of a bribery surge in global
